What You Should Know:
- CerpassRx, a leader in pharmacy benefit management (PBM), today announced the launch of the Intelligent Specialty Engine, an AI-enabled platform powered by Waltz Health to manage specialty drug spend.
- CerpassRx’s innovative approach includes real-time analytics and specialty spend management capabilities that drive significant cost savings, improve transparency and optimize the specialty drug experience for health plan customers and their members – or self-insured
Read More
Drug Research
PathAI and GlaxoSmithKline Partner to Accelerate Research and Drug Development
What You Should Know:
- PathAI and GSK announced a multi-year strategic artificial intelligence (AI) partnership today with a focus on accelerating research and- building drug development programs in oncology and non-alcoholic steatohepatitis (NASH).
- As part of the partnership, GSK will leverage both PathAI’s expertise and models to advance GSK’s proprietary AI models and focus on designing better models to deliver improved treatment options for patients with cancer
Read More
AWS and Pfizer Accelerate Drug Development and Clinical Manufacturing
What You Should Know:
Amazon Web Services (AWS) announced it is working with Pfizer to create innovative, cloud-based solutions to accelerate drug development and clinical manufacturing for testing in clinical trials.
Today, Amazon Web Services, Inc. (AWS) announced that it is working with Pfizer to create innovative, cloud-based solutions with the potential to improve how new medicines are developed, manufactured, and distributed for testing in clinical trials. The companies are
Read More
Mission Bio Launches Single-Cell Multi-Omics System for Precision Cancer Therapies
What You Should Know:
- Mission Bio launches industry’s first and only
single-cell multi-omics platform, is announcing the launch of its most
comprehensive instrument to-date, to save the industry billions of dollars in
drug development costs and bring life-saving treatments to market at least six months
faster.
- Mission Bio’s Tapestri Platform, the first single-cell platform capable of detecting DNA and protein changes simultaneously, gives a profound insight into the mutations that
Read More
Exscientia to Screen 15,000 Drugs in Search for Coronavirus Treatment
What You Should Know:
- Exscientia announced a joint transatlantic initiative with Diamond Light Source, the UK's national synchrotron facility and Calibr, a division of Scripps Research (USA), to screen nearly every known approved and investigational drug against key COVID-19 drug targets to progress compounds that could rapidly become viable drugs for the rapid treatment of the coronavirus.
- Exscientia has gained access to Calibr’s world’s leading collection of 15,000 clinically-ready
Read More
Analysis: Applying AI in the Fight Against The Coronavirus
Drug discovery is a notoriously long, complex and expensive process requiring the concerted efforts of the world’s brightest minds. The complexity in understanding human physiology and molecular mechanisms is increasing with every new research paper published and for every new compound tested. As the world is facing a new challenge in trying to both adapt to and defend itself against the coronavirus, artificial intelligence is offering new hope that a cure might be developed faster than ever
Read More
Life Image, Graticule Partner to Help Biopharma Accelerate Drug Development
- Life Image partners with Graticule to help biopharma realize the full potential of advanced data in real-world evidence programs.
- Partnership combines Life Image’s global medical evidence network specializing in imaging data with Graticule’s deep expertise applying advanced data to high-value use cases.
Life Image, the world’s largest medical evidence network for clinical and imaging data has announced a new partnership with Graticule to help life sciences companies accelerate drug
Read More
Clinical Operations Makes Highest Use of Artificial Intelligence, Tufts Study Finds
Clinical operations function makes the highest use of artificial intelligence (AI) (61%), followed by pharmacovigilance/safety/risk management (57%), and information technology (IT) (55%), according to an analysis recently completed by the Tufts Center for the Study of Drug Development. The analysis, summarized in the May/June Tufts CSDD Impact Report, reveals the pharmaceutical industry is adopting artificial intelligence (AI) on numerous fronts, from discovery and clinical development to risk
Read More
AdoRx Therapeutics, J&J Team Up to Develop Novel Lung Cancer Therapeutics
AdoRx Therapeutics, a UK based drug discovery company, and Johnson & Johnson are teaming up to develop novel therapeutics for the treatment of lung cancer. As part of the strategic collaboration, AdoRx has granted an exclusive option to research, develop and commercialize novel antagonists within the AdoRx portfolio, and the groups will collaborate on drug discovery and preclinical development activities. AdoRx Therapeutics is pursuing the discovery of new therapeutics for cancer-based on
Read More
H1 Launches ‘Strategy as a Service’ Offering for Life Science Companies
H1, a company helping healthcare organizations with live data insights to help fight diseases, today launched a new Strategy as a Service offering designed to help clients accelerate the market research phase of drug development.The company’s new DaVinci service begins at $10,000, which can help clients cut time-to-market in half, spans:- Market Landscape: Validate your strategy against an up-to-date, comprehensive picture of products and patient needs in your market.- Competitive
Read More
